Author and Country | Study design | CVD population | Sample size | Mean age | %female | Intervention/Control | Intervention duration |
---|---|---|---|---|---|---|---|
Forman et al.2014, USA [22] | quasi-experimental study | phaseIICR | 26 | 59 (43–76) | 23 | I: HC mobile app + CR no controlled | 30 days |
Harzand et al.2018, USA [23] | quasi-experimental study | CHD referred to CR | 21 | 65 | 0 | I: commercially available smartphone platform+ CR; no controlled | 12 weeks |
Laustsen et al. 2018, Denmark [24] | quasi-experimental study | CR | 34 | 58 (25–72) | 18 | I: SportsMedicin app with HR monitoring + CR; no controlled | 12 weeks |
Rosario et al.2018, Australia [25] | RCT | CR | 66 | ns | ns | I: STAHR app with health monitoring + CR; C: TCR | 6 weeks |
Skobel et al.2017, German [26] | RCT | phaseIICR | 118 | 59 (45–73) | 11 | I: GEx system intervention + CR; C: TCR | 6 weeks |
Varnfield et al.2014, Australia [27] | RCT | post-MI referred to CR | 94 | 55 | 13 | I: CAP-CR; C: TCR | 6 weeks |
Widmer et al.2015, USA [28] | Controlled, non-Randomized before–after study | ACS referred to CR | 76 | 66 | 27 | I1: PHA mobile app + CR; I2: PHA mobile app + P-CR; C1: TCR; C2: P-TCR | 3 months |
Widmer et al. 2017, USA [29] | RCT | ACS referred to CR | 71 | 63 | 18 | I: PHA mobile app + TCR; C: TCR | 3 months |